DCas9/CRISPR-based Methylation of O-6-methylguanine-DNA Methyltransferase Enhances Chemosensitivity to Temozolomide in Malignant Glioma

Overview

Journal J Neurooncol

Publisher Springer

Date 2024 Jan 15

PMID 38224404

Authors

Serendipity Zapanta Rinonos

Tie Li

Sean Thomas Pianka

Terry J Prins

Blaine S. C. Eldred

Bryan M Kevan

Linda M Liau

Phioanh Leia Nghiemphu

Timothy F Cloughesy

Albert Lai

Affiliations

Soon will be listed here.

Abstract

Background: Malignant glioma carries a poor prognosis despite current therapeutic modalities. Standard of care therapy consists of surgical resection, fractionated radiotherapy concurrently administered with temozolomide (TMZ), a DNA-alkylating chemotherapeutic agent, followed by adjuvant TMZ. O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme, removes alkylated lesions from tumor DNA, thereby promoting chemoresistance. MGMT promoter methylation status predicts responsiveness to TMZ; patients harboring unmethylated MGMT (~60% of glioblastoma) have a poorer prognosis with limited treatment benefits from TMZ.

Methods: Via lentiviral-mediated delivery into LN18 glioma cells, we employed deactivated Cas9-CRISPR technology to target the MGMT promoter and enhancer regions for methylation, as mediated by the catalytic domain of the methylation enzyme DNMT3A. Methylation patterns were examined at a clonal level in regions containing Differentially Methylation Regions (DMR1, DMR2) and the Methylation Specific PCR (MSP) region used for clinical assessment of MGMT methylation status. Correlative studies of genomic and transcriptomic effects of dCas9/CRISPR-based methylation were performed via Illumina 850K methylation array platform and bulk RNA-Seq analysis.

Results: We used the dCas9/DNMT3A catalytic domain to achieve targeted MGMT methylation at specific CpG clusters in the vicinity of promoter, enhancer, DMRs and MSP regions. Consequently, we observed MGMT downregulation and enhanced glioma chemosensitivity in survival assays in vitro, with minimal off-target effects.

Conclusion: dCas9/CRISPR is a viable method of epigenetic editing, using the DNMT3A catalytic domain. This study provides initial proof-of-principle for CRISPR technology applications in malignant glioma, laying groundwork for subsequent translational studies, with implications for future epigenetic editing-based clinical applications.

Citing Articles

Cell-Based Glioma Models for Anticancer Drug Screening: From Conventional Adherent Cell Cultures to Tumor-Specific Three-Dimensional Constructs.

Lanskikh D, Kuziakova O, Baklanov I, Penkova A, Doroshenko V, Buriak I Cells. 2025; 13(24.

PMID: 39768176 PMC: 11674823. DOI: 10.3390/cells13242085.

Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma.

Jacome M, Wu Q, Pina Y, Etame A Cancers (Basel). 2024; 16(21).

PMID: 39518074 PMC: 11544870. DOI: 10.3390/cancers16213635.

Two decades of progress in glioma methylation research: the rise of temozolomide resistance and immunotherapy insights.

Huo X, Li H, Xing Y, Liu W, Chen P, Du F Front Neurosci. 2024; 18:1440756.

PMID: 39286478 PMC: 11402815. DOI: 10.3389/fnins.2024.1440756.

References

Remington M, Chtchetinin J, Ancheta K, Nghiemphu P, Cloughesy T, Lai A . The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Neuro Oncol. 2008; 11(1):22-32. PMC: 2718956. DOI: 10.1215/15228517-2008-080. View

McDonald J, Celik H, Rois L, Fishberger G, Fowler T, Rees R . Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation. Biol Open. 2016; 5(6):866-74. PMC: 4920199. DOI: 10.1242/bio.019067. View

Brandes A, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V . Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009; 115(15):3512-8. DOI: 10.1002/cncr.24406. View

Liu X, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S . Editing DNA Methylation in the Mammalian Genome. Cell. 2016; 167(1):233-247.e17. PMC: 5062609. DOI: 10.1016/j.cell.2016.08.056. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

Schilsky R, Dolan M, Bertucci D, Ewesuedo R, Vogelzang N, Mani S . Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000; 6(8):3025-31. View

Wiestler B, Claus R, Hartlieb S, Schliesser M, Weiss E, Hielscher T . Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol. 2013; 15(8):1017-26. PMC: 3714152. DOI: 10.1093/neuonc/not043. View

Ceccarelli M, Barthel F, Malta T, Sabedot T, Salama S, Murray B . Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. PMC: 4754110. DOI: 10.1016/j.cell.2015.12.028. View

Stepper P, Kungulovski G, Jurkowska R, Chandra T, Krueger F, Reinhardt R . Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase. Nucleic Acids Res. 2016; 45(4):1703-1713. PMC: 5389507. DOI: 10.1093/nar/gkw1112. View

10.

Malley D, Hamoudi R, Kocialkowski S, Pearson D, Collins V, Ichimura K . A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol. 2011; 121(5):651-61. DOI: 10.1007/s00401-011-0803-5. View

11.

Happold C, Roth P, Wick W, Schmidt N, Florea A, Silginer M . Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem. 2012; 122(2):444-55. DOI: 10.1111/j.1471-4159.2012.07781.x. View

12.

Takashima H, Tsuji A, Saga T, Yasunaga M, Koga Y, Kuroda J . Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Sci Rep. 2017; 7(1):12341. PMC: 5615035. DOI: 10.1038/s41598-017-12563-5. View

13.

Lalezari S, Chou A, Tran A, Solis O, Khanlou N, Chen W . Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol. 2013; 15(3):370-81. PMC: 3578486. DOI: 10.1093/neuonc/nos308. View

14.

Quinn J, Jiang S, Reardon D, Desjardins A, Vredenburgh J, Rich J . Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol. 2009; 11(5):556-61. PMC: 2765345. DOI: 10.1215/15228517-2009-007. View

15.

Amabile A, Migliara A, Capasso P, Biffi M, Cittaro D, Naldini L . Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. Cell. 2016; 167(1):219-232.e14. PMC: 5039111. DOI: 10.1016/j.cell.2016.09.006. View

16.

Aryee M, Jaffe A, Corrada-Bravo H, Ladd-Acosta C, Feinberg A, Hansen K . Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014; 30(10):1363-9. PMC: 4016708. DOI: 10.1093/bioinformatics/btu049. View

17.

Bady P, Sciuscio D, Diserens A, Bloch J, van den Bent M, Marosi C . MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012; 124(4):547-60. PMC: 3444709. DOI: 10.1007/s00401-012-1016-2. View

18.

Malmstrom A, Gronberg B, Marosi C, Stupp R, Frappaz D, Schultz H . Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13(9):916-26. DOI: 10.1016/S1470-2045(12)70265-6. View

19.

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

20.

Ostrom Q, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C . CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017; 19(suppl_5):v1-v88. PMC: 5693142. DOI: 10.1093/neuonc/nox158. View